The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.53% | -2.37% | 13.34% | 16.76% | 11.32% | 9.52% | N/A | N/A | N/A | N/A | 18.23% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -7.53% | -2.37% | 13.34% | 16.76% | 11.32% | 19.98% | N/A | N/A | N/A | N/A | 57.2% |
| Rank within category | 11/19 | 6/18 | 5/18 | 6/18 | 4/17 | 2/14 | N/A | N/A | N/A | N/A | N/A |
| Sector Funds | 2024 | 2025 | 2026 |
|---|---|---|---|
| Yearly returns | N/A | 0.09% | 14.45% |
| Q1 returns | N/A | -7.15% | -2.52% |
| Q2 returns | 5.99% | 6.24% | 19.15% |
| Q3 returns | 23.13% | -0.1% | 3.45% |
| Q4 returns | 5.61% | 1.58% | -4.74% |
1% on or before 1M, Nil after 1M
| Alpha | 0.474499 |
| Beta | 0.998 |
| Sharpe Ratio | 0.297473 |
| Sortino Ratio | 0.629699 |
| R-Squared | 0.9429 |
| Tracking Error | 0.9569 |
| Downside Risk | 15.9935 |
| Std. Deviation (Annualised) | 14.2355 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| WhiteOak Capital Pharma and Healthcare Fund - Regular Plan - Growth Current | -7.53% | -2.37% | 13.34% | 16.76% | 11.32% | N/A | N/A | N/A | 18.23% | 926.55 | 2.76 | 0.30 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.36% |
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.11% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.26% |
| Clearing Corporation of India Ltd | Cash & Cash Equivalents and Net Assets | 5.55% | |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.91% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 3.75% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.68% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.28% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.88% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.81% |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.60% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 2.35% |
| CORONA Remedies Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.34% |
| Thyrocare Technologies Ltd. | Healthcare Services | Domestic Equities | 2.27% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.09% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.01% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 1.85% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 1.84% |
| Shaily Engineering Plastics Ltd. | Consumer Durables | Domestic Equities | 1.84% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 1.82% |
| Narayana Hrudayalaya Ltd. | Healthcare Services | Domestic Equities | 1.61% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.57% |
| Vijaya Diagnostic Centre Ltd. | Healthcare Services | Domestic Equities | 1.56% |
| Onesource Specialty Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.55% |
| Acutaas Chemicals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.45% |
| Navin Fluorine International Ltd. | Chemicals & Petrochemicals | Domestic Equities | 1.41% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 1.36% |
| Aarti Pharmalabs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.20% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.20% |
| Procter & Gamble Health Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.18% |
| Molbio Diagnostics Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 1.15% |
| Rainbow Children's Medicare Ltd. | Healthcare Services | Domestic Equities | 1.15% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.06% |
| Aether Industries Ltd. | Chemicals & Petrochemicals | Domestic Equities | 1.05% |
| Kovai Medical Center & Hospital Ltd. | Healthcare Services | Domestic Equities | 0.95% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.93% |
| Senores Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.80% |
| Jupiter Life Line Hospitals Ltd. | Healthcare Services | Domestic Equities | 0.73% |
| Supriya Lifescience Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.69% |
| Vimta Labs Ltd. | Healthcare Services | Domestic Equities | 0.67% |
| Innova Captab Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.63% |
| 91 Days Tbill (MD 05/11/2026) | Treasury Bills | 0.60% | |
| 91 Days Tbill (MD 03/12/2026) | Treasury Bills | 0.60% | |
| Nephrocare Health Services Ltd. | Healthcare Services | Domestic Equities | 0.57% |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | 0.57% | |
| 91 Days Tbill (MD 10/12/2026) | Treasury Bills | 0.53% | |
| Manipal Health Enterprises Ltd. | Healthcare Services | Domestic Equities | 0.52% |
| 182 Days Tbill (MD 05/11/2026) | Treasury Bills | 0.47% | |
| Sudeep Pharma Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.46% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.42% |
| Tatva Chintan Pharma Chem Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.42% |
| Orchid Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.41% |
| Zota Health Care Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.40% |
| 91 Days Tbill (MD 29/10/2026) | Treasury Bills | 0.37% | |
| 91 Days Tbill (MD 19/11/2026) | Treasury Bills | 0.32% | |
| Evonile Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.24% |
| Laxmi Dental Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.23% |
| 91 Days Tbill (MD 22/10/2026) | Treasury Bills | 0.17% | |
| Bharat Parenterals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.10% |
| 182 Days Tbill (MD 12/11/2026) | Treasury Bills | 0.08% | |
| 364 Days Tbill (MD 12/11/2026) | Treasury Bills | 0.01% | |
| Total | 100.00% | ||
Prior to joining WhiteOak Capital, he held the office of Head-Fixed Income at BOI AXA Investment Managers. Earlier, he was a portfolio manager at Morgan Stanley Investment Management. Piyush holds a PGDBM from SPJIMR Mumbai with specialization in finance, and a B.E. (E&C) from MIT Manipal. He has also completed the CFA Certification Course conducted by the CFA Institute, USA.
Before joining WhiteOak, Ramesh founded Ashoka Capital Advisers, which advised a fund and several family offices on investments in South Asia. Earlier, he was part of a two-member team at Alden Global Capital, a US-based hedge fund, where he managed investments in the region for over seven years. He began his career as an analyst at CRISIL (majority-owned by Standard & Poor’s), India’s leading rating agency, where he covered the financial sector. Ramesh is a CFA charterholder, an MBA from the Faculty of Management Studies (FMS), Delhi, and has passed the Chartered Accountancy course.
Mr. Agrawal has over 12 years of experience as Sales Trader servicing FII/FPIs, Insurance companies and Mutual Funds in the Institutional Equities broking business across multiple organizations. Prior to joining Motilal Oswal Asset Management Company Ltd., he was Vice President - Sales Trader at Citigroup Global Markets Ltd. Earlier, he has worked as an Associate Director with RBS Equities India Limited between 2009-10 and worked as Senior Manager - Institutional Equities, with Edelweiss Capital between 2005 to 2009.Mr. Agrawal, is a PGDBM (Finance) from Institute of Management Technology, Ghaziabad and Bachelor of Commerce from University of Lucknow.
Prior to joining WhiteOak, Dheeresh served as an Executive Director at Goldman Sachs Asset Management. Through his 14 year stint at Goldman Sachs he covered a wide range of sectors including Healthcare, Chemicals, Telecom & Media, Logistics, Building Material and Retail. At Goldman Sachs India Equity Fund , Dheeresh was among the top rated professional generating the highest alpha per unit of capital. He holds a B.E in Electronics Engineering from Punjab Engineering College (Gold Medalist) and a PGDBM from MDI Gurgaon.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
